SEC Form SC 13G/A filed by Edgewise Therapeutics Inc. (Amendment)
$EWTX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/25/2025 | $20.00 | Neutral | Goldman |
| 7/30/2025 | $46.00 | Strong Buy | Raymond James |
| 6/30/2025 | $42.00 | Buy | H.C. Wainwright |
| 4/30/2025 | $41.00 | Buy | Guggenheim |
| 4/2/2025 | $14.00 | Sector Outperform → Sector Perform | Scotiabank |
| 3/7/2025 | $50.00 | Sector Outperform | Scotiabank |
| 1/22/2025 | $30.00 | Hold | Stifel |
| 11/22/2024 | $45.00 | Outperform | Evercore ISI |
Goldman initiated coverage of Edgewise Therapeutics with a rating of Neutral and set a new price target of $20.00
Raymond James initiated coverage of Edgewise Therapeutics with a rating of Strong Buy and set a new price target of $46.00
H.C. Wainwright initiated coverage of Edgewise Therapeutics with a rating of Buy and set a new price target of $42.00
144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)
144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)
144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
BOULDER, Colo., Feb. 5, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that Behrad Derakhshan, Ph.D., Chief Operating Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026 at 3:00 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcas
BOULDER, Colo., Feb. 2, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on January 30, 2025, Edgewise granted inducement stock options to purchase a total of 198,250 shares of Edgewise's common stock to 7 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan (the "Inducement Plan").
- Advancing robust clinical pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions - - Presenting at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 8:15 am PT (11:15 am ET) - BOULDER, Colo., Jan. 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today provided updates on the Company's clinical programs and highlighted major milestones for 2026. Edgewise Chief Executive Officer, Kevin Koch, Ph.D., will present these updates today at the J.P. Morgan 2026 Healthcare Conference.
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
BOULDER, Colo., Nov. 20, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development. "We are thrilled to welcome Chris to our Board of Directors," said Kevin Koch, Ph.D., President and Chief Executive Officer. "His commercial expertise and launch leadersh
BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced the appointment of Michael Nofi, as Chief Financial Officer (CFO), effective November 10, 2025. Mr. Nofi joins Edgewise after serving as Chief Accounting Officer (CAO) at SpringWorks Therapeutics, Inc. Mr. Nofi will succeed Edgewise CFO, R. Michael Carruthers, who is retiring. "As we enter a pivotal stage in our Company's evolution, we a
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. "With over 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene to our Board," said Kevin Koch, Ph.D., President and Chief Executive Officer. "Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful to count her as a valued advisor as we contin
– Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed – – Management hosting webcast to discuss findings on September 12 at 8:30 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today pos
– EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – – EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation to 15 mg daily for all patients – – Management hosting webcast to discuss findings on June 21 at 9:00 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month
- Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022. Edgewise ARCH Interi
SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
SC 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)